Romilkimab Completed Phase 2 Trials for Systemic Sclerosis (SSc) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02921971Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis